MYC and small cell lung carcinoma: Other agents that are currently being evaluated are: chiauranib, an aurora B kinase inhibitor for relapsed SCLC (NCT03216343), GSK525762, a BET inhibitor as monotherapy for patients harboring MYC amplification (NCT01587703), and in combination with trametinib for patients carrying RAS mutations (NCT03266159).